To further address the clinical relevance of CDC25A in STS, its mRNA expression levels were examined in a broad series of patient samples (n = 149) gathered from a public TCGA data set [32] including 26 leiomyosarcomas, 89 liposarcomas, 34 myxofibrosarcomas and 9 control adipose tissue samples. This evidence concerns the gene CDC25A and myxofibrosarcoma.